Publications by authors named "Delee Maxson"

Claim this Profile
C
Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Eamon M Berge, Xian Lu, Delee Maxson, Anna E Barón, Shirish M Gadgeel

Clin Lung Cancer· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.
D Ross Camidge, Margaret Skokan, Porntip Kiatsimkul, Barbara Helfrich, Xian Lu, DeLee Maxson

Cancer· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.
Robert C Doebele, Xian Lu, Christopher Sumey, Delee A Maxson, Andrew J Weickhardt

Cancer· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.
D Ross Camidge, Mariana Theodoro, Delee A Maxson, Margaret Skokan, Tara O'Brien

Cancer· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.
Andrew Weickhardt, Robert Doebele, Ana Oton, Janice Lettieri, DeLee Maxson

J Thorac Oncol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis